One strategy is to combine with histone deacetylase (HDAC) inhibitors, since B-ALL is often characterized by epigenetic changes that silence the expression of pro-apoptotic factors. Here, HDAC9 is linked to precursor B-cell acute lymphoblastic leukemia.